1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Song, J.
Gilquin, B.
Jamin, N.
Guenneugues, M.
Dauplais, M.
Vita, C.
Menez, A.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
1
90.00
90.00
90.00
1.000
1.000
1.000
C4 H9 N O2
103.120
n
ALPHA-AMINOBUTYRIC ACID
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C5 H7 N O3
129.114
n
PYROGLUTAMIC ACID
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C11 H12 N2 O2
204.225
y
TRYPTOPHAN
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
US
Biochemistry
BICHAW
0033
0006-2960
36
3760
3766
10.1021/bi962720h
9092804
NMR solution structure of a two-disulfide derivative of charybdotoxin: structural evidence for conservation of scorpion toxin alpha/beta motif and its hydrophobic side chain packing.
1997
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
4273.921
CHARYBDOTOXIN
1
man
polymer
CHABII
no
yes
(PCA)FTNVSCTTSKE(ABA)WSVCQRLHNTSRGKCMNKK(ABA)RCYS
QFTNVSCTTSKEAWSVCQRLHNTSRGKCMNKKARCYS
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
Egyptian scorpion
Leiurus
sample
6883
Leiurus quinquestriatus
entity_poly
pdbx_database_status
pdbx_struct_assembly
pdbx_struct_mod_residue
pdbx_struct_oper_list
struct_conn
struct_ref_seq_dif
struct_ref_seq_dif
repository
Initial release
Version format compliance
Version format compliance
Database references
Derived calculations
Other
Polymer sequence
Database references
1
0
1997-01-11
1
1
2008-03-24
1
2
2011-07-13
2
0
2019-12-25
2
1
2020-01-15
_entity_poly.pdbx_seq_one_letter_code_can
_pdbx_database_status.process_site
_pdbx_struct_mod_residue.parent_comp_id
_struct_conn.pdbx_leaving_atom_flag
_struct_ref_seq_dif.details
_struct_ref_seq_dif.details
Y
BNL
1996-06-06
REL
REL
30
6.3
278
K
BRUNGER
refinement
X-PLOR
PCA
1
n
1
PCA
1
A
PHE
2
n
2
PHE
2
A
THR
3
n
3
THR
3
A
ASN
4
n
4
ASN
4
A
VAL
5
n
5
VAL
5
A
SER
6
n
6
SER
6
A
CYS
7
n
7
CYS
7
A
THR
8
n
8
THR
8
A
THR
9
n
9
THR
9
A
SER
10
n
10
SER
10
A
LYS
11
n
11
LYS
11
A
GLU
12
n
12
GLU
12
A
ABA
13
n
13
ABA
13
A
TRP
14
n
14
TRP
14
A
SER
15
n
15
SER
15
A
VAL
16
n
16
VAL
16
A
CYS
17
n
17
CYS
17
A
GLN
18
n
18
GLN
18
A
ARG
19
n
19
ARG
19
A
LEU
20
n
20
LEU
20
A
HIS
21
n
21
HIS
21
A
ASN
22
n
22
ASN
22
A
THR
23
n
23
THR
23
A
SER
24
n
24
SER
24
A
ARG
25
n
25
ARG
25
A
GLY
26
n
26
GLY
26
A
LYS
27
n
27
LYS
27
A
CYS
28
n
28
CYS
28
A
MET
29
n
29
MET
29
A
ASN
30
n
30
ASN
30
A
LYS
31
n
31
LYS
31
A
LYS
32
n
32
LYS
32
A
ABA
33
n
33
ABA
33
A
ARG
34
n
34
ARG
34
A
CYS
35
n
35
CYS
35
A
TYR
36
n
36
TYR
36
A
SER
37
n
37
SER
37
A
author_defined_assembly
1
monomeric
A
PCA
1
PYROGLUTAMIC ACID
A
PCA
1
GLN
A
ABA
13
ALPHA-AMINOBUTYRIC ACID
A
ABA
13
ALA
A
ABA
33
ALPHA-AMINOBUTYRIC ACID
A
ABA
33
ALA
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
identity operation
0.0000000000
0.0000000000
0.0000000000
17
A
HIS
21
0.081
SIDE CHAIN
22
A
TYR
36
0.070
SIDE CHAIN
13
8.70
1.10
114.20
122.90
A
A
A
CA
CB
SG
CYS
CYS
CYS
28
28
28
N
20
9.14
1.10
114.20
123.34
A
A
A
CA
CB
SG
CYS
CYS
CYS
28
28
28
N
22
7.25
1.10
114.20
121.45
A
A
A
CA
CB
SG
CYS
CYS
CYS
28
28
28
N
23
7.47
1.10
114.20
121.67
A
A
A
CA
CB
SG
CYS
CYS
CYS
28
28
28
N
27
7.58
1.10
114.20
121.78
A
A
A
CA
CB
SG
CYS
CYS
CYS
28
28
28
N
28
9.19
1.10
114.20
123.39
A
A
A
CA
CB
SG
CYS
CYS
CYS
28
28
28
N
1
A
ASN
4
-141.02
53.90
1
A
LYS
11
-172.54
-35.32
1
A
HIS
21
-106.06
-112.18
1
A
ASN
22
-179.88
60.52
1
A
SER
24
-144.98
20.07
1
A
MET
29
-99.03
-122.10
1
A
LYS
31
-144.72
-1.06
2
A
LYS
11
-177.36
-44.86
2
A
HIS
21
-101.83
-114.09
2
A
ASN
22
-177.70
59.38
2
A
SER
24
-145.14
36.18
2
A
LYS
27
-125.83
-145.61
2
A
MET
29
-97.21
-121.92
2
A
LYS
31
-144.82
-2.36
3
A
ASN
4
-144.82
54.70
3
A
LYS
11
-175.61
-36.07
3
A
HIS
21
-103.05
-110.60
3
A
ASN
22
-178.85
63.92
3
A
MET
29
-100.07
-119.68
4
A
ASN
4
-150.40
55.43
4
A
VAL
5
-102.85
-167.07
4
A
LYS
11
-168.21
-34.90
4
A
HIS
21
-115.78
-115.16
4
A
ASN
22
-173.98
58.32
4
A
LYS
27
-135.79
-151.34
4
A
MET
29
-98.94
-123.27
4
A
LYS
31
-144.97
-1.56
5
A
LYS
11
-177.25
-39.25
5
A
HIS
21
-116.60
-118.12
5
A
ASN
22
-173.86
59.34
5
A
SER
24
-132.84
-32.13
5
A
LYS
27
-108.72
-147.83
5
A
MET
29
-95.18
-124.74
5
A
LYS
31
-142.19
-7.28
6
A
ASN
4
-148.94
49.29
6
A
THR
8
-126.45
-56.11
6
A
LYS
11
179.75
-45.94
6
A
HIS
21
-100.31
-113.70
6
A
ASN
22
-175.86
56.80
6
A
SER
24
-131.62
-33.00
6
A
LYS
27
-126.29
-141.60
6
A
MET
29
-98.83
-125.85
7
A
ASN
4
-145.56
54.24
7
A
VAL
5
-103.64
-169.73
7
A
LYS
11
-178.70
-39.18
7
A
HIS
21
-118.22
-116.19
7
A
ASN
22
-172.07
59.17
7
A
LYS
27
-127.06
-149.48
7
A
MET
29
-99.38
-121.23
7
A
LYS
31
-140.93
-6.55
8
A
ASN
4
-141.87
45.31
8
A
THR
8
-123.34
-54.06
8
A
LYS
11
-173.19
-34.61
8
A
HIS
21
-122.38
-116.59
8
A
ASN
22
-173.09
57.77
8
A
MET
29
-96.70
-123.17
9
A
THR
8
-132.08
-47.86
9
A
LYS
11
-177.64
-33.64
9
A
HIS
21
-99.66
-112.32
9
A
ASN
22
178.30
63.73
9
A
LYS
27
-109.86
-139.46
9
A
MET
29
-99.32
-121.56
9
A
TYR
36
-143.87
59.66
10
A
THR
8
-130.81
-46.92
10
A
LYS
11
-171.18
-46.79
10
A
LEU
20
-90.07
-68.20
10
A
HIS
21
-104.13
-114.65
10
A
ASN
22
-178.13
82.18
10
A
SER
24
-144.96
28.78
10
A
MET
29
-101.73
-122.13
11
A
ASN
4
-148.13
57.25
11
A
THR
8
-131.11
-47.89
11
A
LYS
11
-171.98
-45.67
11
A
LEU
20
-90.01
-64.78
11
A
HIS
21
-99.45
-112.94
11
A
ASN
22
-176.47
59.04
11
A
SER
24
-145.11
19.00
11
A
LYS
27
-117.37
-143.25
11
A
MET
29
-96.16
-125.48
12
A
ASN
4
-141.01
51.39
12
A
THR
8
-130.41
-48.39
12
A
LYS
11
-171.10
-41.81
12
A
HIS
21
-104.73
-113.27
12
A
ASN
22
-177.17
65.25
12
A
SER
24
-134.63
-33.05
12
A
LYS
27
-133.63
-140.35
12
A
MET
29
-96.16
-126.18
12
A
LYS
31
-142.37
-1.52
13
A
ASN
4
-146.86
52.67
13
A
THR
8
-131.38
-52.56
13
A
LYS
11
-171.57
-36.73
13
A
HIS
21
-122.25
-116.67
13
A
ASN
22
-173.55
63.21
13
A
SER
24
-142.06
35.82
13
A
LYS
27
-127.05
-146.25
13
A
MET
29
-109.03
-132.48
14
A
ASN
4
-147.83
49.38
14
A
THR
8
-123.99
-53.05
14
A
LYS
11
-171.04
-42.03
14
A
HIS
21
-109.35
-112.59
14
A
ASN
22
-172.71
55.57
14
A
LYS
27
-114.13
-140.92
14
A
MET
29
-94.97
-121.47
15
A
ASN
4
-141.09
57.88
15
A
VAL
5
-104.28
-167.23
15
A
HIS
21
-118.28
-117.83
15
A
ASN
22
-170.02
61.29
15
A
LYS
27
-145.01
-156.37
15
A
MET
29
-99.72
-121.47
15
A
LYS
31
-144.76
-0.88
16
A
ASN
4
-151.74
49.43
16
A
THR
8
-125.48
-52.65
16
A
LYS
11
-174.38
-36.08
16
A
LEU
20
-90.09
-73.16
16
A
SER
24
-145.03
32.20
16
A
MET
29
-97.27
-121.96
16
A
LYS
31
-142.03
-4.11
17
A
ASN
4
-147.59
54.33
17
A
LYS
11
-175.79
-31.36
17
A
HIS
21
-99.97
-115.60
17
A
ASN
22
-177.74
58.57
17
A
LYS
27
-132.41
-139.62
17
A
MET
29
-95.31
-123.96
17
A
LYS
31
-140.98
-3.11
18
A
ASN
4
-149.02
48.20
18
A
THR
8
-130.19
-49.06
18
A
LYS
11
-175.02
-35.69
18
A
HIS
21
-122.33
-114.51
18
A
ASN
22
-173.32
58.02
18
A
SER
24
-145.09
37.97
18
A
MET
29
-97.10
-121.88
19
A
VAL
5
-102.29
-167.87
19
A
LYS
11
-174.64
-43.00
19
A
HIS
21
-109.83
-116.05
19
A
ASN
22
-173.00
57.42
19
A
THR
23
-144.71
-156.95
19
A
SER
24
-145.10
-2.42
19
A
MET
29
-99.62
-121.81
20
A
ASN
4
-142.22
52.27
20
A
THR
8
-132.85
-52.75
20
A
LYS
11
-163.29
-37.12
20
A
LEU
20
-90.06
-67.97
20
A
HIS
21
-102.73
-114.83
20
A
ASN
22
-175.55
58.18
20
A
LYS
27
-129.09
-146.00
20
A
MET
29
-107.12
-128.82
21
A
ASN
4
-149.89
53.30
21
A
THR
8
-130.41
-47.21
21
A
LYS
11
-172.74
-32.26
21
A
HIS
21
-119.36
-115.38
21
A
ASN
22
-177.06
58.80
21
A
LYS
27
-114.03
-146.78
21
A
MET
29
-97.10
-124.06
22
A
THR
8
-124.77
-56.77
22
A
SER
10
-90.04
57.80
22
A
LYS
11
-168.33
-33.33
22
A
LEU
20
-90.13
-61.91
22
A
HIS
21
-106.21
-112.74
22
A
ASN
22
-175.72
57.80
22
A
LYS
27
-144.98
-150.36
22
A
MET
29
-105.72
-130.20
22
A
LYS
31
-140.91
-3.05
23
A
ASN
4
-141.91
56.16
23
A
THR
8
-130.11
-55.36
23
A
LYS
11
-170.09
-42.48
23
A
HIS
21
-101.62
-112.57
23
A
ASN
22
-174.98
57.98
23
A
SER
24
-144.98
23.61
23
A
MET
29
-99.45
-122.61
24
A
THR
8
-131.39
-47.76
24
A
LYS
11
-173.44
-43.29
24
A
HIS
21
-100.68
-114.54
24
A
ASN
22
-177.73
61.27
24
A
LYS
27
-107.97
-149.47
24
A
MET
29
-95.00
-119.32
24
A
LYS
31
-140.12
-11.58
25
A
THR
8
-132.33
-45.91
25
A
LYS
11
-173.51
-35.61
25
A
HIS
21
-115.09
-119.04
25
A
ASN
22
-175.21
62.42
25
A
LYS
27
-106.95
-143.35
25
A
MET
29
-98.42
-118.75
25
A
LYS
31
-131.56
-35.11
26
A
ASN
4
-145.36
52.95
26
A
LYS
11
-173.94
-38.83
26
A
HIS
21
-118.88
-119.08
26
A
ASN
22
-174.92
56.35
26
A
LYS
27
-127.86
-149.50
26
A
MET
29
-98.61
-128.26
26
A
LYS
31
-140.46
-3.74
27
A
ASN
4
-146.69
52.56
27
A
THR
8
-123.25
-57.79
27
A
LYS
11
-165.45
-35.81
27
A
HIS
21
-101.84
-115.10
27
A
ASN
22
179.86
60.95
27
A
LYS
27
-144.96
-154.42
27
A
MET
29
-107.63
-132.02
28
A
ASN
4
-148.29
49.99
28
A
THR
8
-128.66
-51.38
28
A
LYS
11
-173.93
-42.49
28
A
HIS
21
-118.97
-116.31
28
A
ASN
22
-175.84
59.74
28
A
SER
24
-144.89
32.62
28
A
MET
29
-106.73
-131.62
29
A
ASN
4
-155.51
52.30
29
A
LYS
11
-173.79
-36.42
29
A
HIS
21
-115.94
-119.08
29
A
ASN
22
-170.88
58.15
29
A
LYS
27
-112.13
-140.53
29
A
MET
29
-97.55
-122.52
30
A
ASN
4
-149.16
54.02
30
A
THR
8
-131.48
-47.23
30
A
LYS
11
-173.06
-38.63
30
A
HIS
21
-104.05
-114.36
30
A
ASN
22
179.56
60.30
30
A
SER
24
-141.72
17.29
30
A
MET
29
-98.50
-122.72
model building
X-PLOR
refinement
X-PLOR
phasing
X-PLOR
CHARYBDOTOXIN
A TWO DISULFIDE DERIVATIVE OF CHARYBDOTOXIN WITH DISULFIDE 13-33 REPLACED BY TWO ALPHA-AMINOBUTYRIC ACIDS, NMR, 30 STRUCTURES
1
Y
N
A
SER
10
A
SER
10
HELX_P
A
LEU
20
A
LEU
20
1
1
11
disulf
2.028
A
CYS
7
A
SG
CYS
7
1_555
A
CYS
28
A
SG
CYS
28
1_555
disulf
2.039
A
CYS
17
A
SG
CYS
17
1_555
A
CYS
35
A
SG
CYS
35
1_555
covale
1.358
both
A
PCA
1
A
C
PCA
1
1_555
A
PHE
2
A
N
PHE
2
1_555
covale
1.359
both
A
ABA
13
A
N
ABA
13
1_555
A
GLU
12
A
C
GLU
12
1_555
covale
1.364
both
A
ABA
13
A
C
ABA
13
1_555
A
TRP
14
A
N
TRP
14
1_555
covale
1.369
both
A
ABA
33
A
N
ABA
33
1_555
A
LYS
32
A
C
LYS
32
1_555
covale
1.355
both
A
ABA
33
A
C
ABA
33
1_555
A
ARG
34
A
N
ARG
34
1_555
TOXIN
CHARYBDOTOXIN, NEUROTOXIN, POTASSIUM CHANNEL INHIBITOR, TOXIN
SCKA_LEIQH
UNP
1
1
P13487
QFTNVSCTTSKECWSVCQRLHNTSRGKCMNKKCRCYS
2
37
1BAH
2
37
P13487
A
1
2
37
1
CYS
modified residue
ABA
13
1BAH
A
P13487
UNP
13
13
1
CYS
modified residue
ABA
33
1BAH
A
P13487
UNP
33
33
2
anti-parallel
A
ARG
25
A
ARG
25
A
MET
29
A
MET
29
A
LYS
32
A
LYS
32
A
TYR
36
A
TYR
36
1
P 1